Literature DB >> 15256465

Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel.

Elizabeth Hopper-Borge1, Zhe-Sheng Chen, Irina Shchaveleva, Martin G Belinsky, Gary D Kruh.   

Abstract

The multidrug resistance protein (MRP) family consists of nine members that can be categorized according to whether or not a third (NH(2)-terminal) membrane-spanning domain is present. Three (MRP1, MRP2, and MRP3) of the four members that have this structural feature are able to confer resistance to natural product anticancer agents. We previously established that MRP7, the remaining family member that has three membrane-spanning domains, possesses the cardinal biochemical activity of MRPs in that it is able to transport amphipathic anions such as 17beta-estradiol 17-(beta-d-glucuronide). However, the drug resistance profile of the pump has not been determined. In this study, the drug resistance capabilities of MRP7 are evaluated by analyzing the resistance profiles of two clones of HEK293 cells in which the pump was ectopically expressed. MRP7-transfected HEK293 cells exhibited the highest levels of resistance toward docetaxel (9-13-fold). In addition, lower levels of resistance were observed for paclitaxel (3-fold), vincristine (3-fold), and vinblastine (3-4-fold). Consistent with the operation of an ATP-dependent efflux pump, MRP7-transfected cells exhibited reduced accumulation of radiolabeled paclitaxel compared with HEK293 cells transfected with parental plasmid. These results indicate that MRP7, unlike other MRPs, is a resistance factor for taxanes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15256465     DOI: 10.1158/0008-5472.CAN-03-3111

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  51 in total

1.  Anti-neoplastic agent thymoquinone induces degradation of α and β tubulin proteins in human cancer cells without affecting their level in normal human fibroblasts.

Authors:  Mahmoud Alhosin; Abdulkhaleg Ibrahim; Abdelaziz Boukhari; Tanveer Sharif; Jean-Pierre Gies; Cyril Auger; Valérie B Schini-Kerth
Journal:  Invest New Drugs       Date:  2011-09-01       Impact factor: 3.850

Review 2.  Multidrug Resistance Proteins (MRPs) and Cancer Therapy.

Authors:  Yun-Kai Zhang; Yi-Jun Wang; Pranav Gupta; Zhe-Sheng Chen
Journal:  AAPS J       Date:  2015-04-04       Impact factor: 4.009

Review 3.  Taccalonolides: Novel microtubule stabilizers with clinical potential.

Authors:  April L Risinger; Susan L Mooberry
Journal:  Cancer Lett       Date:  2009-10-31       Impact factor: 8.679

4.  Identification of a human ABCC10 orthologue in Catharanthus roseus reveals a U12-type intron determinant for the N-terminal domain feature.

Authors:  Taissir El-Guizani; Clotilde Guibert; Saida Triki; Benoit St-Pierre; Eric Ducos
Journal:  J Genet       Date:  2014-04       Impact factor: 1.166

5.  Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice.

Authors:  Elizabeth A Hopper-Borge; Timothy Churchill; Chelsy Paulose; Emmanuelle Nicolas; Joely D Jacobs; Olivia Ngo; Yehong Kuang; Alex Grinberg; Heiner Westphal; Zhe-Sheng Chen; Andres J Klein-Szanto; Martin G Belinsky; Gary D Kruh
Journal:  Cancer Res       Date:  2011-05-15       Impact factor: 12.701

6.  Role of the OATP Transporter Family and a Benzbromarone-SensitiveEfflux Transporter in the Hepatocellular Disposition of Vincristine.

Authors:  Johan Nicolaï; Louise Thevelin; Qi Bing; Bruno Stieger; Hugues Chanteux; Patrick Augustijns; Pieter Annaert
Journal:  Pharm Res       Date:  2017-08-21       Impact factor: 4.200

7.  Impact of intertumoral heterogeneity on predicting chemotherapy response of BRCA1-deficient mammary tumors.

Authors:  Sven Rottenberg; Marieke A Vollebergh; Bas de Hoon; Jorma de Ronde; Philip C Schouten; Ariena Kersbergen; Serge A L Zander; Marina Pajic; Janneke E Jaspers; Martijn Jonkers; Martin Lodén; Wendy Sol; Eline van der Burg; Jelle Wesseling; Jean-Pierre Gillet; Michael M Gottesman; Joost Gribnau; Lodewyk Wessels; Sabine C Linn; Jos Jonkers; Piet Borst
Journal:  Cancer Res       Date:  2012-03-06       Impact factor: 12.701

Review 8.  Clinical pharmacokinetics of docetaxel : recent developments.

Authors:  Sharyn D Baker; Alex Sparreboom; Jaap Verweij
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 9.  Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases.

Authors:  Zhe-Sheng Chen; Amit K Tiwari
Journal:  FEBS J       Date:  2011-08-01       Impact factor: 5.542

10.  Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10).

Authors:  Tong Shen; Ye-Hong Kuang; Charles R Ashby; Yu Lei; Angel Chen; Ying Zhou; Xiang Chen; Amit K Tiwari; Elizabeth Hopper-Borge; Jiangyong Ouyang; Zhe-Sheng Chen
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.